The drug, named THX-110, is a combination of dronabinol (a synthetic cannabinoid ) and palmitoylethanolamide. The company now plans to take it into a randomized, double-blind, placebo controlled study to evaluate its efficacy, in addition to a 24-week extension phase of the trial read out today. Read More
The post Therapix shares rise on early data of its repurposed cannabinoid in Tourette syndrome appeared first on Dagga Magazine.